Kaplan Matthew L. 4
4 · Nuvectis Pharma, Inc. · Filed Jun 13, 2024
Insider Transaction Report
Form 4
Kaplan Matthew L.
Director
Transactions
- Award
Common Stock
2024-06-13+30,000→ 83,760 total
Footnotes (1)
- [F1]The 30,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the board on such dates.